• Blog Home
• Molecular
• News/Events
• Quality Control
• Stabilization
• Sed-rate

CHMP positive about Pfizer’s new combination antibiotic

In a recent announcement, Pfizer, Inc. shared that the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization to EMBLAVEO^®, a new antibiotic for treatment of adults with several types of infections, including those caused by resistant aerobic Gram-negative microorganisms.

One of the most common defenses against Gram-negative bacteria is beta-lactam antimicrobials, which inhibit synthesis of the bacterial cell wall to prevent growth. But over time, bacteria have developed clever mechanisms to avoid killing by beta-lactams, including an enzyme that breaks down the antimicrobial before it can alter the cell wall.  

Developed jointly by Abbvie and Pfizer, EMBLAVEO is a combination of an older beta-lactam antimicrobial, aztreonam, and a newer beta-lactamase inhibitor, avibactam. Pfizer and the CHMP hope that this new antibiotic will offer relief to patients suffering from life-threatening Gram-negative bacterial infections that currently do not have much in the way of treatment options.

To review Pfizer’s press release on EMBLAVEO, click the button below:

Analyze with ease and certainty.

Successful surveillance of antimicrobial resistant bacterial infections depends on identification of specific gene families responsible for resistance. The Streck ARM-D^® kits are a comprehensive, easy to use, and cost-effective way of detecting these gene families in many Gram-negative bacteria.

Learn more about Streck ARM-D Kits

Streck ARM-D Kits are for Research Use Only. Not for use in diagnostic procedures.